Afuco™ Anti-Human MADCAM1 ADCC Recombinant Antibody (PF-00547659), ADCC Enhanced (CAT#: AFC-489CL)

Figure 1 Immunohistochemical staining of endothelium expressing MAdCAM in human colon.

(A) negative control, (B) PF-00547659 staining, arrows indicate specific endothelial staining in the gut lamina propria. The bar represents 200 µm. MAdCAM, mucosal addressin cell adhesion molecule.

Pullen, N., Molloy, E., Carter, D., Syntin, P., Clemo, F., Finco-Kent, D., ... & Sreckovic, S. (2009). Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody. British journal of pharmacology, 157(2), 281-293.

Figure 2 Mean serum concentration of PF-00547659 following increasing i.v. doses in cynomolgus macaques.

Data are plotted as means ± SD (n = 4). Pharmacokinetic data from both males and females are represented together as a single mean.

Pullen, N., Molloy, E., Carter, D., Syntin, P., Clemo, F., Finco-Kent, D., ... & Sreckovic, S. (2009). Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody. British journal of pharmacology, 157(2), 281-293.

Figure 3 Changes in the levels of leukocyte populations over time in response to increasing doses of PF-00547659 over the pre-dose baseline in cynomolgus macaques.

(A) mean % change in the absolute number of total lymphocytes. Data are plotted as means ± standard error of means (SEM; n = 4); ***P < 0.005 over 0.01 and 0.05 mg·kg−1 groups, P = 0.01 over 0.1 mg·kg−1 group; (B) mean % change in the absolute number of CD3+ lymphocytes. Data are plotted as means ± SEM (n = 4); ***P < 0.005 over 0.01 and 0.01 mg·kg−1 groups, P = 0.008 over 0.05 mg·kg−1 group; (C) mean % change in the absolute number of CD4+ lymphocytes. Data are plotted as means ± SEM (n = 4); ***P < 0.005 over 0.01 and 0.1 mg·kg−1 groups, P = 0.009 over 0.05 mg·kg−1 group; (D) mean % change in the absolute number of CD8+ lymphocytes. Data are plotted as means ± SEM (n = 4); ***P < 0.005 over 0.01 mg·kg−1 group, P < 0.05 for 0.05 and 0.1 mg·kg−1 groups; (E) mean % change in the absolute number of CD20+ lymphocytes. Data are plotted as means ± SEM (n = 4); **P < 0.05 over 0.01, 0.05 and 0.1 mg·kg−1 groups; (F) mean % change in the absolute number of CD16+ lymphocytes.

Pullen, N., Molloy, E., Carter, D., Syntin, P., Clemo, F., Finco-Kent, D., ... & Sreckovic, S. (2009). Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody. British journal of pharmacology, 157(2), 281-293.

Figure 4 Fold change in β7+ populations of T-cells following increasing intravenous doses of PF-00547659 over pre-dose baseline levels in the cynomolgus macaque.

(A) Mean fold change in the population of β7+ naive T-cells following escalating intravenous doses of PF-00547659 (0.01–1 mg·kg−1) was determined by a change in the absolute cell number over the pre-dose levels. Data are plotted as means ± SEM (n = 4); **P = 0.007 and 0.009 for 0.01 and 0.05 mg·kg−1 groups respectively; (B) Mean fold change in the population of β7+ effector memory T-cells following escalating intravenous doses of PF-00547659 (0.01–1 mg·kg−1). Data are plotted as means ± SEM (n = 4); *, p < 0.05 over the 0.01 mg/kg group; (C) Mean fold change in the population of β7+ central memory T-cells following escalating intravenous doses of PF-00547659 (0.01–1 mg·kg−1), as determined by a change in the absolute cell number over the pre-dose levels. Data are plotted as means ± SEM (n = 4); **, p = 0.002 and 0.008 for 0.01 and 0.05 mg·kg−1 groups respectively; (D) Mean fold change in the population of β7− central memory T-cells following escalating intravenous doses of PF-00547659 (0.01–1 mg·kg−1).

Pullen, N., Molloy, E., Carter, D., Syntin, P., Clemo, F., Finco-Kent, D., ... & Sreckovic, S. (2009). Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody. British journal of pharmacology, 157(2), 281-293.